UNLABELLED: Purpose: To analyze the efficacy and safety of vaporization of the prostate (VP) with the 150-W thulium:yttrium-aluminum-garnet (Tm:YAG) laser. PATIENTS AND METHODS: In a prospective series of 55 patients with small- and medium-size prostates undergoing major outpatient surgery (MOS), the primary objectives were to analyze changes in maximum flow (Qmax) and International Prostate Symptom Score (IPSS) after 6 months. Immediate (<30 days) and late (>30 days) complications were subsequently recorded. RESULTS: An increase in mean Qmax of 9.33 mL/s (95% confidence interval [CI] of the mean difference 6.73-11.93; P<0.001) was recorded, and mean IPSS was reduced by 16.88 points (95% CI 14.22-19.54; P<0.001). The immediate complications recorded were acute urinary retention (one patient), urinary tract infection without fever (two patients), and macroscopic hematuria (two patients). The only late complication observed was bladder neck sclerosis (one patient). CONCLUSION: After 6 months, VP with 150-W Tm:YAG presents promising results in the clinical improvement of patients with small- and medium-size prostates. Its complication rate is low and it offers excellent hemostasis. The data from our study provide the basis for the design of clinical trials to compare this technique with other procedures.
UNLABELLED: Purpose: To analyze the efficacy and safety of vaporization of the prostate (VP) with the 150-W thulium:yttrium-aluminum-garnet (Tm:YAG) laser. PATIENTS AND METHODS: In a prospective series of 55 patients with small- and medium-size prostates undergoing major outpatient surgery (MOS), the primary objectives were to analyze changes in maximum flow (Qmax) and International Prostate Symptom Score (IPSS) after 6 months. Immediate (<30 days) and late (>30 days) complications were subsequently recorded. RESULTS: An increase in mean Qmax of 9.33 mL/s (95% confidence interval [CI] of the mean difference 6.73-11.93; P<0.001) was recorded, and mean IPSS was reduced by 16.88 points (95% CI 14.22-19.54; P<0.001). The immediate complications recorded were acute urinary retention (one patient), urinary tract infection without fever (two patients), and macroscopic hematuria (two patients). The only late complication observed was bladder neck sclerosis (one patient). CONCLUSION: After 6 months, VP with 150-W Tm:YAG presents promising results in the clinical improvement of patients with small- and medium-size prostates. Its complication rate is low and it offers excellent hemostasis. The data from our study provide the basis for the design of clinical trials to compare this technique with other procedures.
Authors: Thomas R W Herrmann; Evangelos N Liatsikos; Udo Nagele; Olivier Traxer; Axel S Merseburger Journal: Eur Urol Date: 2012-01-17 Impact factor: 20.096
Authors: Gunnar Wendt-Nordahl; Stephanie Huckele; Patrick Honeck; Peter Alken; Thomas Knoll; Maurice Stephan Michel; Axel Häcker Journal: J Endourol Date: 2008-05 Impact factor: 2.942
Authors: Oliver Reich; Christian Gratzke; Alexander Bachmann; Michael Seitz; Boris Schlenker; Peter Hermanek; Nicholas Lack; Christian G Stief Journal: J Urol Date: 2008-05-21 Impact factor: 7.450
Authors: Karin S Coyne; Steven A Kaplan; Christopher R Chapple; Chris C Sexton; Zoe S Kopp; Elizabeth N Bush; Lalitha P Aiyer Journal: BJU Int Date: 2009-04 Impact factor: 5.588